Incyte Closes $1.25 Billion Vega Deal to Expand Hematology Pipeline
WILMINGTON, DE — Incyte (Nasdaq: INCY) has completed its $1.25 billion acquisition of Vega Therapeutics, adding a Phase 3 treatment candidate for von Willebrand disease to its late-stage hematology pipeline …
Incyte Closes $1.25 Billion Vega Deal to Expand Hematology Pipeline Read More